The Liquid Embolic Agent for the Treatment of Brain Arteriovenous Malformation

NCT ID: NCT07314047

Last Updated: 2026-01-02

Basic Information

• Recruitment Status: RECRUITING
• Clinical Phase: NA
• Total Enrollment: 116 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2024-05-28
• Study Completion Date: 2026-05-28

Brief Summary

This study is designed as a prospective, multi-center, open-label, non-inferiority, randomized controlled clinical trial. The control device is Onyx Liquid Embolic System marketed by Micro Therapeutics Inc. DBA ev3 Neurovascular (NMPA (J) 20173136690). According to the inclusion and exclusion criteria specified in this trial protocol, approximately 116 subjects with brain arteriovenous malformation will be enrolled for interventional embolization treatment. The subjects will undergo follow-up before the surgery, after device implantation, at discharge, 1 month (± 7 days), 6 months (± 30 days), and 12 months (± 60 days) after the first embolization. When necessary, unscheduled follow-up will be conducted to record various indicators for evaluating the safety and effectiveness of liquid embolic agents in the treatment of brain arteriovenous malformations.

Conditions

Brain Arteriovenous Malformation; Arteriovenous Fistula

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Liquid embolic agent

Liquid embolic agent developed and manufactured by MicroPort NeuroTech.Liquid embolic agents are used to embolize cerebrovascular malformations during the procedure.

Group Type: EXPERIMENTAL

liquid embolic agent

Intervention Type: DEVICE

liquid embolic agent

the Onyx Liquid Embolic System

The Onyx Liquid Embolic System was developed and manufactured by Micro Therapeutics Inc. DBA ev3 Neurovascular. The Onyx Liquid Embolic System is used to embolize cerebrovascular malformations during the procedure.

Group Type: ACTIVE_COMPARATOR

liquid embolic agent

Intervention Type: DEVICE

liquid embolic agent

Interventions

liquid embolic agent

liquid embolic agent

Intervention Type: DEVICE

Eligibility Criteria

Inclusion Criteria

• Age ≥ 18 and ≤ 80 years at the time of signing the informed consent
• Subjects with brain arteriovenous malformation diagnosed by CT/MRI/DSA
• The target brain arteriovenous malformation is classified by Spetzler-Martin in the range of Ⅰ ~ Ⅳ
• Subjects themselves and/or their guardian are able to understand the purpose of the study, consent to participate, and sign the informed consent form
• Brain arteriovenous malformations deemed suitable for liquid embolic agent intervention as assessed by the investigator

Exclusion Criteria

• Multiple brain arteriovenous malformations
• Brain arteriovenous malformation complicated with blood flow-related aneurysm that may require staged and delayed treatment using other methods within the one-year follow-up period
• Brain arteriovenous malformation with a history of stereotactic radiosurgery within 3 years
• Brain arteriovenous malformation with bleeding within 1 week
• Brain arteriovenous malformation with an expected number of embolizations ≥ 4
• Brain arteriovenous malformation scheduled for surgical resection after embolization
• mRS score ≥ 3
• Subjects unsuitable for anesthesia or endovascular surgical treatment, due to major diseases of cardio, lung, liver, spleen or kidney, malignant brain tumors, severe active infection, disseminated intravascular coagulation, or a history of severe mental illness, etc
• Subjects who undergo major surgical procedures (such as tumor resection, vital organ surgery, etc.) within 30 days prior to signing the informed consent form, or those scheduled for such procedures within 60 days after signing the informed consent form
• Contraindications for liquid embolic agent treatment, including but not limited to: contraindications for DSA, severe allergy or intolerance to contrast agents, severe allergy or intolerance to antiplatelet or anticoagulant medications required for treatment, or severe allergy to tantalum metal
• Pregnant or lactating women
• Subjects participating in other drug or device studies that have not reached their endpoints or who have just withdrawn from the group for less than one month

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 80 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

MicroPort NeuroTech Co., Ltd.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

Shanghai Changhai Hospital

Shanghai, Shanghai Municipality, China

Site Status: RECRUITING

Countries

China

Central Contacts

Liu Shugen

Role: CONTACT

Shugen.Liu@microport.com

18353892888

Facility Contacts

Li qiang

Role: primary

Other Identifiers

LAVA-2023-01-CIP-00

Identifier Type: -

Identifier Source: org_study_id